{"entity":{"id":"ssgj-706","kind":"drug","name":"SSGJ-706","aka":[],"tldr":"SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.","summary":"SSGJ-706 is a bispecific antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and PD-L1. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07171606, plans to enrol 240 participants with primary completion was scheduled for 2026-08-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of SSGJ-706","url":"https://clinicaltrials.gov/search?intr=SSGJ-706"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pd1","pdl1"],"drugs":[],"companies":["3sbio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07171606"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"Bispecific antibody directed at PD-1 and PD-L1, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ssgj-706/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/"}],"trial":[{"id":"nct07233850","kind":"trial","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","route":"/trials/nct07233850/"},{"id":"nct07171606","kind":"trial","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","route":"/trials/nct07171606/"}]}}